Edgewise Therapeutics Correlations
EWTX Stock | USD 32.08 0.12 0.37% |
The current 90-days correlation between Edgewise Therapeutics and Ikena Oncology is 0.09 (i.e., Significant diversification). The correlation of Edgewise Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Edgewise Therapeutics Correlation With Market
Significant diversification
The correlation between Edgewise Therapeutics and DJI is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Edgewise |
Moving together with Edgewise Stock
0.76 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.69 | NAMS | NewAmsterdam Pharma | PairCorr |
0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
0.77 | ABEO | Abeona Therapeutics | PairCorr |
0.69 | SGMO | Sangamo Therapeutics Buyout Trend | PairCorr |
0.76 | AVTE | Aerovate Therapeutics | PairCorr |
0.87 | CRVS | Corvus Pharmaceuticals | PairCorr |
Moving against Edgewise Stock
0.96 | FDMT | 4D Molecular Therapeutics | PairCorr |
0.84 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.72 | RGNX | Regenxbio | PairCorr |
0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.64 | INKT | Mink Therapeutics | PairCorr |
0.58 | PEPG | PepGen | PairCorr |
0.4 | PIRS | Pieris Pharmaceuticals | PairCorr |
0.37 | MREO | Mereo BioPharma Group | PairCorr |
0.9 | BDTX | Black Diamond Therap | PairCorr |
0.85 | ADAP | Adaptimmune Therapeutics | PairCorr |
0.65 | STOK | Stoke Therapeutics | PairCorr |
0.57 | AFMD | Affimed NV | PairCorr |
0.49 | COLL | Collegium Pharmaceutical | PairCorr |
0.36 | ANEB | Anebulo Pharmaceuticals | PairCorr |
0.31 | ACRV | Acrivon Therapeutics, | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Edgewise Stock performing well and Edgewise Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Edgewise Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
IKNA | 0.90 | (0.11) | 0.00 | (0.09) | 0.00 | 1.80 | 5.87 | |||
ELYM | 3.87 | (0.92) | 0.00 | (2.63) | 0.00 | 6.21 | 34.87 | |||
HCWB | 13.10 | 3.70 | 0.32 | (0.97) | 8.25 | 22.00 | 352.85 | |||
RNXT | 3.47 | 0.47 | 0.09 | 1.00 | 3.88 | 7.55 | 40.06 | |||
TPST | 3.90 | (0.60) | 0.00 | (0.58) | 0.00 | 6.38 | 29.55 | |||
SCPH | 2.76 | (0.63) | 0.00 | (0.24) | 0.00 | 4.30 | 20.70 | |||
MIST | 1.85 | 0.22 | 0.13 | 0.26 | 1.57 | 7.19 | 18.66 | |||
MCRB | 4.93 | 0.32 | 0.04 | 1.12 | 5.57 | 10.84 | 28.84 | |||
LUMO | 2.35 | 0.27 | 0.03 | (0.28) | 2.95 | 5.95 | 16.25 |
Edgewise Therapeutics Corporate Management
Badreddin Edris | CoFounder Director | Profile | |
John Moore | General Counsel | Profile | |
Behrad Derakhshan | Chief Officer | Profile | |
Marc MD | Chief Officer | Profile | |
John JD | General Counsel | Profile |